Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) FCF Margin (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed FCF Margin for 15 consecutive years, with 461.23% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 37469.0% to 461.23% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 399.81% through Dec 2025, down 21609.0% year-over-year, with the annual reading at 399.81% for FY2025, 21609.0% down from the prior year.
  • FCF Margin for Q4 2025 was 461.23% at Plus Therapeutics, down from 183.04% in the prior quarter.
  • The five-year high for FCF Margin was 1251.01% in Q1 2021, with the low at 5828.77% in Q3 2022.
  • Average FCF Margin over 5 years is 686.84%, with a median of 253.71% recorded in 2024.
  • The sharpest move saw FCF Margin soared 577402bps in 2023, then crashed -37469bps in 2025.
  • Over 5 years, FCF Margin stood at 1251.01% in 2021, then tumbled by -249bps to 1859.84% in 2022, then skyrocketed by 92bps to 146.46% in 2023, then skyrocketed by 41bps to 86.54% in 2024, then plummeted by -433bps to 461.23% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 461.23%, 183.04%, and 417.63% for Q4 2025, Q3 2025, and Q2 2025 respectively.